Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care

NCT01410383 is registered in ClinicalTrials.gov with Karo Bio AB as lead sponsor.

NCT NCT01410383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01410383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care
Lead sponsor
Karo Bio AB
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2011
Completion date
October 31, 2014
Enrollment
236 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolaemia